---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-013503"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:30:11.506765+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Oncotelic subsidiary Sapu Nano unveils Deciparticle platform; two Phase 1 assets at BIO-Europe

## Summary
- Sapu Nano to present Deciparticle platform and clinical pipeline at BIO-Europe Spring 2026 on March 25.
- Two lead candidates: Sapu003 (everolimus IV) in Phase 1, Sapu006 (docetaxel) entering Phase 1.
- Deciparticle is sub-20 nm nanomedicine for hydrophobic drugs, aiming to improve PK and reduce toxicities.
- Sapu Nano seeking strategic partnerships to accelerate development.

## SEC filing metadata
- accession: 0001493152-26-013503
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315226013503/0001493152-26-013503-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315226013503/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-013503
- JSON: https://secwatch.observer/filing/0001493152-26-013503.json
- Plain text: https://secwatch.observer/filing/0001493152-26-013503.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.